Patients with Type 1 and Type 2 diabetes have paid dramatically inflated insulin prices for years. ELG is part of consolidated litigation pursuing manufacturers (Eli Lilly, Novo Nordisk, Sanofi) and pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx) for alleged price-fixing and kickback schemes.
Who is affected
- Patients who paid out-of-pocket for analog insulin
- Self-insured employers and health plans
- Diabetic patients who rationed insulin due to cost
Conditions and diseases
- Financial harm (out-of-pocket overpayment)
- Diabetes complications from rationing (DKA, vision loss, amputation)
